Health insurers had a great year last year. Their stocks benefited from a rotation into value and their profits weathered the inflationary environment as healthcare utilization remained low.‍

Many retirees fall short of their retirement income goals, according to research from Goldman Sachs Asset Management.

The United States' drug regulatory agency declined to approve a drug from Eli Lilly and Co. (LLY).

Big pharma companies often complain about the impact of tougher laws on future drug research. However, the reality is usually more complicated.

Individuals who do not have health insurance have a limited amount of time to obtain coverage for the year 2023 through the public marketplace.